A bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints.
Sign Up to like & getrecommendations! Published in 2022 at "Biometrics"
DOI: 10.1111/biom.13694
Abstract: In the era of targeted therapies and immunotherapies, the traditional drug development paradigm of testing one drug at a time in one indication has become increasingly inefficient. Motivated by a real-world application, we propose a… read more here.
Keywords: bayesian platform; mixed endpoints; platform trial; trial ... See more keywords